Literature DB >> 2157731

Enhancement of varicella-zoster virus plaquing efficiency with an agarose overlay medium.

D L Krah1, T L Schofield, P J Provost.   

Abstract

The infectivity titers of varicella-zoster virus (VZV) are routinely estimated by plaque production in cell culture. In this report, we show that plaque counts for VZV (strain Oka/Merck), in MRC-5 cell cultures, are significantly enhanced (54% average enhancement) by the use of an agarose overlay medium, as compared to a fluid overlay medium. Evidence also is presented that less variability (P less than 0.05) in plaque counts occurs with the use of an agarose overlay medium.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157731     DOI: 10.1016/0166-0934(90)90100-t

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  5 in total

1.  Assessment of virus infection in cultured cells using metabolic monitoring.

Authors:  R Singhvi; J F Markusen; B Ky; B J Horvath; J G Aunins
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

2.  Quantitative measurement of varicella-zoster virus infection by semiautomated flow cytometry.

Authors:  Irina V Gates; Yuhua Zhang; Cindy Shambaugh; Meredith A Bauman; Charles Tan; Jean-Luc Bodmer
Journal:  Appl Environ Microbiol       Date:  2009-02-05       Impact factor: 4.792

3.  Evaluation of a recombinant human gelatin as a substitute for a hydrolyzed porcine gelatin in a refrigerator-stable Oka/Merck live varicella vaccine.

Authors:  Vladimir Liska; Stacey A Bigert; Philip S Bennett; David Olsen; Robert Chang; Carl J Burke
Journal:  J Immune Based Ther Vaccines       Date:  2007-02-23

4.  Standardization of the methods and reference materials used to assess virus content in varicella vaccines.

Authors:  JiYoung Hong; Ho Jung Oh; Naery Lee; Do-Keun Kim; Heui-Seong Yoon; Yeon-Tae Kim; Seokkee Chang; Jae-Hak Park; Hyejoo Chung
Journal:  Virol J       Date:  2015-07-05       Impact factor: 4.099

5.  Antiviral activity of (+)-sattabacin against varicella zoster.

Authors:  Serena R Mancha; Christopher M Regnery; Joshua R Dahlke; Kenneth A Miller; David J Blake
Journal:  Bioorg Med Chem Lett       Date:  2012-11-16       Impact factor: 2.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.